R

Revolution Medicines

Clinical-stage oncology company developing RAS inhibitors

Senior Director, HEOR/RWE - GI

Biology & BiotechConfirmed live in the last 24 hours
Full-timeRemote in USA$232k - $290k

About the Job

Requirements

  • Deep expertise in health economics, outcomes research, patient-reported outcomes, or related fields in the biotechnology or pharmaceutical industry.
  • Experience in oncology health economics and outcomes research and real-world evidence development.
  • A minimum of 10–13 years of relevant experience and an advanced degree in a relevant field (MD, PhD, or PharmD).
  • A track record of high-impact publications in health economics and outcomes research or real-world evidence topics.
  • Proven success influencing payer and Health Technology Assessment strategy and incorporating health economics and outcomes research considerations into clinical development programs.
  • Strong written and interpersonal communication skills, with the ability to present complex technical information clearly.
  • Demonstrated ability to lead evidence-generation initiatives and communicate health economics and outcomes research value to internal senior leadership and external decision-makers.
  • Knowledge and experience in managed care, integrated delivery networks, formulary decision-making, and payment/access models.
  • Ability to establish relationships with experts in real-world evidence and relevant therapeutic areas.

Responsibilities

  • Develop and evolve product health economics and outcomes research/real-world evidence strategy, including integration with development and market access planning.
  • Align with Medical Affairs and Development leadership to design research and deliver evidence consistent with the medical strategy and Integrated Evidence Plan.
  • Deliver health economics and outcomes research/real-world evidence tactics with quality and in alignment with agreed timing.
  • Provide health economics and outcomes research/real-world evidence leadership on matrix teams and working groups.
  • Lead enterprise partnerships with payers, Health Technology Assessment agencies, and global consortia to help shape access strategy, policies, evidence standards, and evidence-generation activities.
  • Work with health economics and outcomes research/real-world evidence and Medical Affairs leadership to ensure critical value insights are communicated to key internal teams.
  • Provide health economics evidence addressing the needs and expectations of patients, healthcare providers, payers, and Health Technology Assessment agencies.
  • Present research findings effectively to internal and external stakeholders to improve internal decision-making and promote wider adoption of research findings across external stakeholders.
  • Facilitate communication of the value proposition of the company’s portfolio, allowing healthcare and formulary professionals to make informed therapeutic decisions.
  • Engage and collaborate with external partners, including payers, healthcare providers, thought leaders, patient advocates, and decision-makers, to establish and maintain partnerships and gather insights into research programs.
  • Facilitate and implement real-world research partnership engagements with leading healthcare, academic, and payer organizations to co-create value evidence and help drive evidence-based optimal care.
  • Stay up to date with and contribute to advancements in health economics methodologies and best practices; support the development of disease-area health economics and outcomes research/real-world evidence capability, establishing best practices, external visibility, and functional excellence across the Medical Affairs network.
  • Identify and interface with health economics and outcomes research and real-world evidence experts and organizations, and profile data sources and related organizations relevant to the company’s portfolio and therapeutic areas.
  • Closely monitor trends in health policy and the payer environment, assess competitive data gaps, and communicate findings to the organization to build industry-leading capabilities and advance evidence-based medicine and health economics research.

Desired Qualifications

  • 10+ years of relevant experience in the pharmaceutical or biotechnology industry.
  • Global launch experience.
  • Experience related to gastrointestinal oncology.

About the Company

Revolution Medicines

Clinical-stage oncology company developing RAS inhibitors

Revolution Medicines develops precision oncology drugs focused on cancers driven by RAS mutations. Its RAS(ON) inhibitors are small molecules that bind the active form of RAS to block cancer signaling, with candidates like Daraxonrasib (RMC-6236), Elironrasib (RMC-6291), and Zoldonrasib (RMC-9805) advancing in global Phase 3 trials. The company funds its research through collaborations, royalties, and upfront funding, and has not yet marketed a product. Its goal is to bring effective RAS-targeted therapies to patients and advance multiple candidates through late-stage trials toward approval, supported by strong cash reserves.

Company size
1,001-5,000
Company stage
IPO
Headquarters
Redwood City, CA
Founded
2014

Recently Posted Jobs

Explore more opportunities at Revolution Medicines

See more jobs